Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
作者信息
Melikhov Oleg, Kruglova Tatiana, Lytkina Karine, Melkonyan Georgy, Prokhorovich Elena, Putsman Gleb, Rodoman Grigory, Vertkin Arkady, Zagrebneva Alena, Stebbing Justin
机构信息
Institute of Clinical Research, Moscow, Russian Federation
City Clinical Hospital No 52, Moscow, Russian Federation.
出版信息
Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.
Abstract
摘要
相似文献
1
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.在2019冠状病毒病中使用 Janus 激酶抑制剂：对522名个体的前瞻性观察系列研究
Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.
2
Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China.用于治疗中重度特应性皮炎的Janus激酶1抑制剂的真实世界有效性和安全性：中国一项单中心前瞻性研究。
Front Med. 2024 Aug;18(4):752-756. doi: 10.1007/s11684-024-1063-9. Epub 2024 Jul 16.
3
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.影响类风湿关节炎患者使用 Janus 激酶抑制剂药物留存率的因素：ANSWER 队列研究。
Sci Rep. 2022 Jan 7;12(1):134. doi: 10.1038/s41598-021-04075-0.
4
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.巴瑞替尼改善了 COVID-19 肺炎患者接受皮质类固醇治疗后的呼吸功能：一项观察性队列研究。
Rheumatology (Oxford). 2021 Jan 5;60(1):399-407. doi: 10.1093/rheumatology/keaa587.
5
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.在真实临床实践中，托法替布与巴瑞替尼治疗类风湿关节炎患者的疗效和安全性：基于倾向评分逆概率治疗加权的分析。
Ann Rheum Dis. 2021 Sep;80(9):1130-1136. doi: 10.1136/annrheumdis-2020-219699. Epub 2021 Apr 7.
6
JAK inhibitors in refractory dermatomyositis: A case series.JAK 抑制剂治疗难治性皮肌炎：病例系列。
Australas J Dermatol. 2024 Nov;65(7):588-592. doi: 10.1111/ajd.14335. Epub 2024 Jun 18.
7
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.真实世界中单中心使用 JAK 抑制剂治疗类风湿关节炎。
Rheumatology (Oxford). 2021 Sep 1;60(9):4048-4054. doi: 10.1093/rheumatology/keaa858.
8
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.2021 年更新的 EULAR 关于在 COVID-19 中使用免疫调节疗法的考虑要点。
Ann Rheum Dis. 2022 Jan;81(1):34-40. doi: 10.1136/annrheumdis-2021-221366. Epub 2021 Oct 7.
9
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.JAK 抑制剂治疗 2019 冠状病毒病（COVID-19）：一项荟萃分析。
Leukemia. 2021 Sep;35(9):2616-2620. doi: 10.1038/s41375-021-01266-6. Epub 2021 May 14.
10
A novel treatment for psoriatic arthritis: Janus kinase inhibitors.银屑病关节炎的一种新型治疗方法：Janus激酶抑制剂。
Chin Med J (Engl). 2020 Apr 20;133(8):959-967. doi: 10.1097/CM9.0000000000000711.
引用本文的文献
1
Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.用于2019冠状病毒病的Janus激酶抑制剂：一项成对和贝叶斯网络荟萃分析。
Front Med (Lausanne). 2022 Nov 23;9:973688. doi: 10.3389/fmed.2022.973688. eCollection 2022.
2
Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review.巴瑞替尼在 COVID-19 治疗中的当前应用及其未来：最新文献综述
Cureus. 2022 Sep 1;14(9):e28680. doi: 10.7759/cureus.28680. eCollection 2022 Sep.
3
Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein.Dok3 可在 TLR4 识别 SARS-CoV-2 刺突蛋白期间抑制中性粒细胞钙卫蛋白的产生。
Front Immunol. 2022 Sep 12;13:996637. doi: 10.3389/fimmu.2022.996637. eCollection 2022.
4
Editorial: Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume I.社论：激酶抑制剂在癌症和新冠治疗中的药理学与生物化学视角，第一卷
Front Pharmacol. 2022 Jun 15;13:916324. doi: 10.3389/fphar.2022.916324. eCollection 2022.
5
Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.托法替布治疗 MDA5 阳性皮肌炎合并坏疽性胆囊炎
Eur J Med Res. 2022 May 15;27(1):68. doi: 10.1186/s40001-022-00693-0.
6
What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19.危重症与创伤科学领域有哪些新进展？一项关于Janus激酶抑制剂对COVID-19入院患者28天死亡率影响的循证分析。
Int J Crit Illn Inj Sci. 2021 Jul-Sep;11(3):109-111. doi: 10.4103/ijciis.ijciis_80_21. Epub 2021 Sep 25.
本文引用的文献
1
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.巴瑞替尼治疗新冠病毒肺炎——满足一项未被满足的需求
N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.JAK 抑制可降低 SARS-CoV-2 的肝脏感染性，并调节炎症反应，从而降低发病率和死亡率。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe4724. Print 2021 Jan.
4
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.巴瑞替尼的美国食品和药物管理局不良事件报告系统（FAERS）事件的真实世界药物不良反应比例分析。
Expert Opin Drug Saf. 2020 Nov;19(11):1505-1511. doi: 10.1080/14740338.2020.1799975. Epub 2020 Jul 31.
5
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.巴利昔替尼的作用机制支持人工智能预测在 COVID-19 患者中的检测。
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
6
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
7
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
Zotero 插件